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ABSTRACT 
 
There are as yet no ideal biomarkers of HIV-associated neurocognitive disorders. As 
astrocytosis is a feature of HIV encephalitis, the marker S100β may hold promise as a 
biomarker of HAND. We explored associations between S100β and neurocognition in 
individuals with HIV in Cape Town, South Africa, before and after antiretroviral therapy 
(ART) was initiated. The S100β levels in the cerebrospinal fluid (CSF) of forty-six participants 
with HIV, but not yet on antiretroviral therapy, was quantified using an enzyme-linked 
immunoassay (ELISA). A battery of cognitive tests was performed and the global deficit 
score (GDS) was calculated. In twenty of these patients, the S100β analysis and the 
cognitive tests were repeated approximately six months after the initiation of ART. There 
was no significant association between cerebrospinal fluid S100β and GDS at baseline (r=    
-0.070; p= 0.66) or after six months of ART (r= 0.16; p= 0.52). Cerebrospinal fluid S100β 
levels at baseline did not predict a change in neurocognition on ART (B(SE) = 0.001, 
(0.001), β=0.025, p=0.85). S100β in the cerebrospinal fluid may not adequately reflect 
neurocognitive impairment in individuals with HIV. Our results further demonstrate that CSF 
S100β levels are not affected by ART, indicating persistent neuroinflammation. 
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1. CONTEXT 
 
Since the advent of antiretroviral therapy (ART), the incidence of HIV-associated dementia 
(HAD) has declined significantly, but the minor HIV-associated neurocognitive disorders 
(HAND) have become more prevalent (Grant et al., 2014).  
 
This has led to two significant quandaries. Firstly, the question arises why HAND persists 
even when patients are virally suppressed on ART. Secondly the diagnosis of HAND has 
become more challenging as individuals with minor cognitive disorders have less severe 
neurocognitive impairment which may be more difficult to detect in busy clinic settings. The 
diagnosis therefore relies on neuropsychological test batteries which are time consuming 
and often difficult to adapt to local settings (Antinori et al., 2007). 
 
Biomarkers of various kinds provide information on different aspects of the 
neuropathogenesis of HAND. S100 calcium-binding protein β (S100β) is a promising 
biomarker as it reflects astrocytosis, which may play a role in the neuropathophysiology of 
HAND. In this study S100β and its relationship with cognitive impairment in HIV-positive 
patients was explored. If S100β is shown to correlate with cognition, it may be useful in 
distinguishing HIV-associated effects as opposed to other causes of cognitive impairment in 
patients with HIV.  It may also help to monitor the response on treatment. This may lead to 
a focus on glial cells such as astrocytes in future neuroprotective strategies. 
 
1.1. HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS 
1.1.1. Pathogenesis 
HIV is neurovirulent and can affect the human nervous system in numerous ways. A key 
neuropathological feature is HIV encephalitis, and the clinical correlate: HIV encephalopathy 
(Cherner et al., 2002). Clinically, HIV-encephalopathy manifests as neurocognitive 
impairment, which when measured alongside functional impairment, results in disorders 
such as HIV dementia (McArthur, Brew, & Nath, 2005). HIV dementia is typically a 
subcortical dementia that includes psychomotor slowing, memory deficits and impairment in 
attention and executive functioning (McArthur et al., 2005). 
 
The pathogenesis of HIV dementia is not completely understood (Morris, Davis, & Brew, 
2010) and it is still unclear why some patients with HIV develop cognitive impairment while 
others are unaffected (McArthur, 2004)(Brew & Letendre, 2008). 
 
It has been proposed that HIV crosses the blood brain barrier (BBB) and enters the central 
nervous system (CNS) as passengers in mononuclear cells that are trafficking to the brain – 
the “Trojan horse theory” (González-Scarano & Martín-García, 2005). Several CNS cell types 
(astrocytes, perivascular macrophages and microglia) come into contact with these infected 
cells (González-Scarano & Martín-García, 2005). HIV may become isolated in macrophages 
in the CNS due to the insufficient penetration of ART into the brain (McArthur et al., 
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2005)(González-Scarano & Martín-García, 2005). Uncontrolled HIV replication in the CNS 
leads to partial breakdown of the BBB, rarefaction of white matter, astrocyte apoptosis, 
dendritic simplification and neuronal loss (McArthur, 2004)(McArthur et al., 2005)(Morris et 
al., 2010). 
 
However, it is still unclear how HIV in the CNS contributes to these neurodegenerative 
changes , especially since neurons are not infected by HIV as they do not express CD4 
receptors (González-Scarano & Martín-García, 2005)(Morris et al., 2010). 
 
One theory is that HIV leads to immune activation disproportionate to the amount of virus 
present in the CNS, and the inflammation eventually leads to neurodegeneration  (González-
Scarano & Martín-García, 2005). There is a correlation between the presence of neurological 
deficits and inflammation of the CNS (McArthur, 2004). The inflammatory process leads to 
changes in the permeability of the BBB and release of pro-chemotactic factors, which allow 
more monocytes to enter the CNS and to perpetuate the cycle of neuroinflammation and 
neurotoxicity (González-Scarano & Martín-García, 2005). 
 
The role of astrocytes in HAND 
 
Astrocytes may play an important role in the neuropathogenesis of HAND. Astrocytes are 
actively involved in many functions of the CNS, including control of extracellular synaptic 
metabolites, neuronal excitability, syncytial signalling, synaptic plasticity, immune activation, 
inflammation and maintenance of the BBB (Eugenin & Berman, 2007). 
 
Early studies using in situ polymerase chain reaction (PCR) demonstrated that approximately 
1% of astrocytes are infected with HIV in patients with HAD (Takahashi, Wesselingh, & 
Griffin, 1996). However, a more sensitive PCR detected HIV deoxyribonucleic acid (DNA) in 
up to 19% of astrocytes in the brains of patients with HAD (Churchill et al., 2009). Most of 
the cells in the brain are astrocytes and they may therefore act as an important reservoir of 
HIV in the CNS (Churchill et al., 2009)(Gray et al., 2014)(T. Wang et al., 2009). However, 
whether astrocytes are susceptible to HIV infection is still questionable since they lack the 
CD4 receptor which is required for HIV entry into the cell (Gray et al., 2014). Recent 
evidence from cell cultures with primary human foetal astrocyte cultures suggest that 
astrocytes trap and internalize HIV-1 virions and engulf fragments of HIV-1-infected 
macrophages and that astrocytes are therefore unlikely to function as long-term viral 
reservoirs within the CNS (Russell et al., 2017).  
 
The infection of astrocytes with HIV is correlated with the severity of the neuropathological 
changes in the brains of patients with HAD (Churchill et al., 2009). Astrocytes are also 
frequently infected in HIV positive subjects with a clinical dementia but no overt 
neuropathology. The infection of astrocytes with HIV may therefore be an explanation for 
HAND in patients who are treated with ART and in whom neuropathology is not evident  
(Churchill et al., 2009). 
 
13 
 
Latent infection of astrocytes causes changes in astrocyte gene expression (Churchill et al., 
2009)(Z. Wang et al., 2004). The interaction between infected macrophages and astrocytes 
impede important astrocyte functions such as the uptake of excitatory amino acids including 
glutamate (González-Scarano & Martín-García, 2005). Activated astrocytes produce tumour 
necrosis factor (TNF) and other cytokines which intensify glutamate release and decreases 
the uptake of glutamate by astrocytes (González-Scarano & Martín-García, 2005) . The 
impaired catabolism of glutamate leads to excitotoxic neuronal death and astrocyte 
apoptosis which eventually leads to BBB compromise (Churchill et al., 2009) (González-
Scarano & Martín-García, 2005)(Gorry, Ong, Thorpe, Bannwarth, & Thompson, 2003). HIV 
infected astrocytes increase the neurotoxicity of HIV infected microglia (T. Wang et al., 
2009). Astrocyte apoptosis occurs commonly and the concentration of apoptotic astrocytes 
relates with how fast HIV dementia progresses (McArthur et al., 2005). 
 
The activation and apoptosis of astrocytes is a significant cause of BBB compromise, as 
astrocytes are essential for the maintenance of BBB integrity (Churchill et al., 2009)(Gray et 
al., 2014) (Z. Wang et al., 2004). Even a small percentage (less than 10%) of HIV-infected 
astrocytes is sufficient to disrupt the BBB by a gap-junction dependent mechanism (Eugenin 
& Berman, 2007). 
 
HIV-infected astrocytes may have an active role in monocyte recruitment across the BBB 
(Churchill et al., 2009) and use gap-junction channels to spread toxic signals to uninfected 
astrocytes and other cells that support viral replication, such as microglia and macrophages 
(Eugenin & Berman, 2007)(Gray et al., 2014). The ability of astrocytes to transfer HIV 
without de novo synthesis of the virus may indicate that astrocytes are able to sequester 
and protect the virus and hence facilitate viral dissemination in the CNS (Gray et al., 2014). 
 
1.1.2. Classification of HAND 
 
The 1991 American Academy of Neurology (AAN) criteria define two categories of HIV-
associated neurologic disease: HAD and minor cognitive motor disorder (MCMD) (Antinori et 
al., 2007).  MCMD is less severe than HAD and consists of impaired cognitive or behavioural 
function as well as mild impairment in work or activities of daily living (ADL) (Antinori et al., 
2007). This set of AAN criteria does not diagnose the persons who have neurocognitive 
impairment but no functional decline (Antinori et al., 2007).   
 
The HIV Neurobehavioral Research Centre (HNRC) at the University of California, San Diego, 
proposed updated research criteria which distinguish the following three conditions: 
asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder 
(MND) and HAD (Antinori et al., 2007). ANI is the most common form of HAND and is, by 
definition, impairment in neuropsychological testing with no obvious impairment in daily 
functioning (Grant et al., 2014) (Antinori et al., 2007). This approach was adopted by the 
AAN in 2007. 
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1.1.3. Epidemiology 
 
Together with the sensory neuropathies, HAND remains one of the commonest neurological 
consequences of HIV (McArthur, 2004)(McArthur et al., 2005). HAND occurs commonly in 
HIV positive patients, even in those who are on ART (Grant et al., 2014). ART does not 
completely protect neurons against the harm done by HIV (McArthur, 2004).  
 
With the advent of ART, the incidence of HAD has declined, but there has been an increase 
in the overall prevalence of HAND (Antinori et al., 2007)(McArthur, 2004)(Morris et al., 
2010)(Eugenin & Berman, 2007). In the CNS HIV Antiretroviral Therapy Effects (CHARTER) 
study, 52% of HIV positive patients on ART had neuropsychiatric impairment (Heaton et al., 
2010). 33% of these patients had ANI, 12% had mild neurocognitive disorder and only 3% 
had HAD.  
 
In South Africa, the prevalence of MND is 42,4% and the prevalence of HAD is 25,4% in 
people living with HIV who are not receiving ART (Joska et al., 2011). 
 
1.1.4. Consequences 
 
Baseline ANI might be a predictor of the time to symptomatic decline (Grant et al., 2014). In 
one study, HIV positive patients with ANI developed other symptoms of HIV much sooner 
than patients without ANI (Grant et al., 2014). 
 
The mild neurocognitive disorders may have a deleterious impact on treatment adherence 
and driving ability (McArthur, 2004). Patients with mild cognitive impairment have a higher 
risk to develop AIDS and HIV encephalitis (McArthur, 2004)(McArthur et al., 2005). Mild 
cognitive impairment can lead to poor adherence to treatment and a non-suppressed viral 
load (McArthur, 2004)(McArthur et al., 2005). Even mild impairment may be associated with 
shortened survival and leads to poor employability (McArthur et al., 2005). 
 
Because of these deleterious consequences and the negative impact on treatment 
adherence, HAND should be identified and treated as soon as possible (McArthur et al., 
2005). Prior to universal test-and-treat, it was important to initiate ART in treatment naïve 
patients. Treated individuals with HAND, who have symptoms (such as adherence 
difficulties) may require assessment of viral load and CSF sampling. In a small proportion, 
the presence of compartmentalisation or escape may require a switch of ART regimen or 
viral genotyping. In those with viral control, adherence support and close follow-up become 
key. ART can improve the neurocognitive effects of HIV dementia and milder degrees of 
HAND (McArthur, 2004)(McArthur et al., 2005). It has been demonstrated that cognition 
continues to improve after even eight weeks on ART and reversal of the neurological deficits 
may therefore be much slower than expected (McArthur, 2004).   
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1.1.5. Diagnosis of HAND 
 
For effective treatment to be initiated HAND needs to be diagnosed early and this remains 
problematic for several reasons: 
1) The diagnostic criteria 
The 1991 AAN criteria did not recognise patients who have neurocognitive impairment but 
no functional decline (Antinori et al., 2007).  In lifestyles or socio-economic situations which 
pose fewer cognitive demands, deterioration in cognition may be less likely to result in 
functional impairment (Antinori et al., 2007). The alternative criteria proposed by the HNRC 
added an additional category, ANI, which requires mild impairment on neuropsychological 
testing but not impairment in daily functioning (Antinori et al., 2007)(Grant et al., 2014). 
However, the criteria for ANI are sensitive but not very specific (Grant et al., 2014). In 
addition, neither of these sets of criteria showed a strong correlation with the diagnosis of 
HIV-encephalitis at autopsy (Antinori et al., 2007).   
 
2) Neuropsychological testing 
The only way to diagnose HAND, using either set of criteria, is by conducting 
neuropsychological testing. Neuropsychological test batteries are time-consuming and the 
performance in these tests is influenced by age, level of education, ethnicity and gender 
(Antinori et al., 2007). Due to these limitations, neuropsychological tests cannot be used for 
screening purposes. The performance of neuropsychological test batteries is not realistic in 
primary health clinics with limited resources and high service demands. Neuropsychological 
tests are also often not capable of detecting an improvement in function (McArthur, 2004).  
 
3) Confounding factors 
Associated conditions, such as depression, substance disorders and hepatitis C infection, 
contribute to the evolution of ANI (Grant et al., 2014). It can be very difficult to decide 
whether neurological deficits are a result of HIV dementia or other confounding factors such 
as diabetes, hepatitis C, cerebrovascular disease or the cognitive effects of old age 
(McArthur et al., 2005).  
 
1.2. Biomarkers in HAND 
 
A biomarker is an indicator of normal biologic processes, pathophysiological processes or 
pharmacologic responses to a therapeutic intervention that can be objectively measured 
(Floyd & Mcshane, 2004). 
 
Biomarkers should be identified for the following reasons: 
 
1) Diagnosis 
The use of biomarkers would be useful in assisting with the diagnosis of HAND and could be 
used as an objective measure for the presence of HAND (Morris et al., 2010)(Brew & 
Letendre, 2008)(Price et al., 2007). Unlike neuropsychological testing, biomarkers are not 
influenced by the cultural background and level of education of the patient (Antinori et al., 
2007) and may be less time consuming to administer (Yuan et al., 2017). 
16 
 
Biomarkers could be used as additional screening tests for HAND. The Society of 
Psychiatrists of South Africa has emphasised the need for routine screening of HIV-positive 
individuals for cognitive impairments (Janse van Rensburg, 2012). Screening instruments for 
cognitive impairment have been developed but these instruments do not always have a 
good sensitivity or specificity and can be time consuming (McArthur, 2004). In South Africa, 
relatively few patients are referred for neuropsychiatric treatment due to inadequate 
screening of these disorders (Janse van Rensburg, 2012). Primary health care providers are 
often extremely busy and under immense pressure which could lead to inadequate 
screening. Biomarkers could be a much more effective way to screen for HIV neurocognitive 
disorders as it is less time consuming and requires no special training or experience. 
 
A diagnostic challenge when identifying HIV related cognitive disorders is excluding other 
illnesses which can account for or exacerbate cognitive symptoms (Price et al., 2007). This 
can be especially challenging in older patients (McArthur, 2004). Biomarkers can help us to 
distinguish between HIV associated cognitive impairment and cognitive impairment as a 
result of other causes. A marker for the severity of HAND could provide an objective 
measure of the proportion of the deficit that was related to HIV, as opposed to the confound 
(Brew & Letendre, 2008). 
 
2) Monitoring 
The fact that ANI increases the risk for symptomatic decline (Grant et al., 2014) is a strong 
argument for the regular monitoring of these patients.  Neuropsychological test batteries 
have traditionally been used for the monitoring of patients with HAND, but these can be 
time consuming, do not always detect an improvement in function and are subject to 
practice effects (McArthur, 2004)(McArthur et al., 2005). Biomarkers could be an objective 
and effective measure to monitor both symptomatic decline and the response to ART (Price 
et al., 2007) (Brew & Letendre, 2008).  
 
3) Identification of subtypes 
Recent data support the existence of different clinical phenotypes of HAND, including an 
inactive form (Brew & Letendre, 2008). There is a need for measures that can assess 
whether HAND is pathologically active or dormant (Price et al., 2007)(Morris et al., 2010). 
The identification of disease activity is clinically important for two reasons. Firstly, 
unrecognised inactive disease may mean that the patient is given new antiretroviral drugs 
needlessly with the consequent increased risk of toxicity (Brew & Letendre, 2008).  
Secondly, the lack of recognition of disease activity in clinical trials could lead to the 
inclusion of a large number of patients with inactive disease (Brew & Letendre, 2008). 
 
4) Pathogenesis 
Our understanding of the pathogenesis of HAND is limited (Morris et al., 2010). The 
investigation of biomarkers can help us to gain a better understanding of disease activity 
(McArthur, 2004). 
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5) Prognosis 
A biomarker that could predict improvement or decline would be extremely helpful (Brew & 
Letendre, 2008) (Morris et al., 2010). Neither plasma nor CSF HIV ribonucleic acid (RNA) 
levels are predictive of neurological deterioration and cognitive decline in patients on ART, 
and this has encouraged the quest for other biomarkers which may better reflect the 
pathogenic mechanisms underlying HAND (McArthur, 2004). 
 
1.3. S100β 
 
S100β is a calcium-binding protein with two helix-loop-helix (EF-hand) motifs connected by 
a central hinge region. S100β is produced primarily by astrocytes in the CNS (Donato, 1999) 
(Donato et al., 2009)(Brew & Letendre, 2008)(Steiner et al., 2007)(Yardan, Erenler, Baydin, 
Aydin, & Cokluk, 2011). 
 
S100β exerts neurotrophic or neurotoxic effects depending on its concentration (Donato, 
1999) (Donato, 2001). At low concentrations, S100β promotes neuritic outgrowth and 
regeneration, and enhanced survival of neurons (Donato, 1999)(Donato, 2001). However, at 
high levels it is neurotoxic and causes apoptosis of neuronal and glial cells (Donato, 
1999)(Donato, 2001).  
 
S100β levels are elevated in several tumours, the ageing brain and in the brains of patients 
affected by Alzheimer’s disease, Down’s syndrome and temporal lobe epilepsy  (Donato, 
1999)(Donato et al., 2009)(Donato, 2001). Elevated S100β levels have even been implicated 
in schizophrenia and dyslexia (Donato et al., 2009).The observation that S100β is elevated 
in these conditions, has led to the idea that S100β might play a role in the pathophysiology 
of neurodegeneration and brain inflammatory diseases (Donato et al., 2009). S100β has 
been implicated in the modulation of learning and memory, and in animal models 
overexpression of S100β was associated with behavioural abnormalities (Donato, 
1999)(Donato, 2001). 
 
S100β is secreted by astrocytes which make it an ideal marker of astrocyte activation or 
astrocytosis (Brew & Letendre, 2008)(Du Pasquier et al., 2013) (Donato et al., 2009). High 
levels of S100β have been associated with neuronal apoptosis, thus decreasing the 
neuroprotective effects of astrocytes and the ability of astrocytes to maintain the integrity of 
the BBB (Du Pasquier et al., 2013) . 
 
S100β could potentially be a biomarker of HIV-associated cognitive impairment for two 
reasons: 
1) S100β is a marker of cognitive impairment in other neurological disorders (Donato, 
1999)(Donato, 2001)(Donato et al., 2009) (Yardan et al., 2011). 
2) Astrocyte infection plays an important role in the development of HAND, and the 
activation and apoptosis of astrocytes may directly lead to HIV encephalopathy and 
cognitive impairment (Churchill et al., 2009). S100β as a marker of astrocytosis may 
therefore reflect the extent of astrocyte involvement in a patient with HIV.  
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However, the evidence for astrocytic marker S100β as a biomarker of cognitive impairment 
in HIV is limited.  
 
Pemberton and Brew (2001) demonstrated that CSF S100β levels correlated with the 
presence, severity and rapidity of the progression of AIDS dementia complex (ADC) in 
patients receiving ART. CSF S100β levels were significantly elevated in patients with 
moderate and severe ADC when compared to patients with no ADC or mild ADC. They 
showed that CSF S100β levels were a good predictor of rapid progression in patients with 
ADC. CSF S100β appeared to be a marker of severe dementia in patients with HIV. Yet, in 
the clinical setting, the milder cognitive disorders create a diagnostic challenge, and it is in 
those disorders where S100β as a biomarker of cognitive impairment would be most useful 
and necessary. 
 
Woods et al. (2010) demonstrated that CSF S100β levels were elevated in HIV positive 
patients with decreased verb generation on neuropsychological testing. S100β was an 
independent predictor of verb generation in patients who received ART and patients who 
were not on treatment. S100β was shown to be a marker of executive dysfunction in 
patients with HIV. S100β levels did not reflect impairment in other cognitive domains.  
 
Abassi et al (2017) showed that HIV positive individuals in Uganda with a CD4 < 200 had 
elevated CSF S100β levels but, paradoxically, that elevated levels of CSF S100β were 
associated with decreased odds of developing MND or HAD. However, in Uganda the 
predominant HIV clade is Clade D unlike South Africa which is Clade C predominant. Clade C 
may have different cognitive outcomes than Clade D and may be less virulent than other 
clades (Paul et al., 2014). They also looked at CSF S100β in ART naïve patients only. Yuan 
et al (2017) showed that CSF S100β levels were higher in cognitively impaired patients than 
in cognitively normal patients with HIV. In contrast to the Abassi study, over 60% of the 
patients in this study were on ART and all of these patients were HIV Clade B (Yuan et al., 
2017). 
 
Estébanez et al. (2014) looked at S100B levels in a group of HIV patients with cognitive 
impairment receiving protease inhibitors as triple-drug therapy or as monotherapy and 
showed no statistical difference in the levels of CSF S100β between the groups. Du Pasquier 
et al. (2013) compared the CSF concentration of S100β in a group of HIV-infected patients 
on lopinavir/ritonavir monotherapy with a group on continued therapy. S100β levels were 
significantly higher in the group receiving monotherapy than in the other group. However, 
neither of these studies looked at the correlation between S100β levels and cognition. 
  
There are no published data on the response of S100β levels on ART (Brew & Letendre, 
2008). According to our knowledge, there are no published South African studies which 
investigated S100β and its relationship to cognition in HAND. This may be key, as HIV in 
southern Africa is predominantly Clade C, which have different neuropathological effects to 
Clade B (Mishra, Vetrivel, Siddappa, Ranga, & Seth, 2008). 
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In this study, we investigated the relationship between S100B levels and cognition in a 
South African sample. We also looked at the association between S100B and cognition after 
a period of ART. 
2. ETHICAL CONSIDERATIONS 
 
The larger HAND research project had been approved by the Human Research Committee of 
the University of Cape Town (HREC 023/2008). The Human Research Committee of the 
University of Cape Town has also approved the current project and the new analyses (HREC 
727/2017). 
 
Participants of the original HAND study signed informed consent for their information and 
blood and CSF samples to be used for subsequent research. However, the sample is still 
sensitive in that confidential information is contained in the recorded data and human CSF 
samples were used.  All information was encoded and identifying names were not recorded 
in the research.  
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ABSTRACT 
 
There are as yet no ideal biomarkers of HIV-associated neurocognitive disorders. As 
astrocytosis is a feature of HIV encephalitis, the marker S100β may hold promise as a 
biomarker of HAND. We explored associations between S100β and neurocognition in 
individuals with HIV in Cape Town, South Africa, before and after antiretroviral therapy 
(ART) was initiated. The S100β levels in the cerebrospinal fluid (CSF) of forty-six participants 
with HIV, but not yet on antiretroviral therapy, was quantified using an enzyme-linked 
immunoassay (ELISA). A battery of cognitive tests was performed and the global deficit 
score (GDS) was calculated. In twenty of these patients, the S100β analysis and the 
cognitive tests were repeated approximately six months after the initiation of ART. There 
was no significant association between cerebrospinal fluid S100β and GDS at baseline (r=    
-0.070; p= 0.66) or after six months of ART (r= 0.16; p= 0.52). Cerebrospinal fluid S100β 
levels at baseline did not predict a change in neurocognition on ART (B(SE) = 0.001, 
(0.001), β=0.025, p=.85). S100β in the cerebrospinal fluid may not adequately reflect 
neurocognitive impairment in individuals with HIV. Our results further demonstrate that CSF 
S100β levels are not affected by ART, indicating persistent neuroinflammation. 
 
INTRODUCTION 
 
The use of anti-retroviral therapy (ART) has dramatically impacted the neurological sequelae 
of HIV. The incidence of HIV-associated dementia (HAD) has declined significantly from 
approximately 20% prior to the use of ART, to less than 5% in the ART era (Janssen, 
Nwanyanwu, Selik, & Stehr-Green, 1992)(Heaton et al., 2010). However, the minor HIV-
associated neurocognitive disorders (HAND) have become more prevalent (Grant et al., 
2014)(Joska et al., 2011).  
 
The diagnosis of HAND requires neuropsychological testing, which is not always widely 
available, or indeed sensitive enough (Antinori et al., 2007). The use of imaging and biofluid 
markers are held out as essential aids to clinical diagnosis, yet none have proved adequately 
sensitive or specific to HAND. The value of biomarkers lies in their potential for rapid assay, 
association with disease progression and/or response to treatment, and in addition are not 
influenced by the cultural background and level of education of the individual (Antinori et al., 
2007)(Morris et al., 2010)(Brew & Letendre, 2008)(Price et al., 2007). 
The persistence of HAND in the face of viral suppression on ART continues to vex research 
efforts. While the pathogenesis of HAND is not completely understood, the latent infection of 
astrocytes with HIV may be a key to understanding ongoing inflammation and the viral 
reservoir (Morris et al., 2010)(McArthur, 2004)(Brew & Letendre, 2008)(Churchill et al., 
2009). Astrocytes form the majority cell type in the CNS, and nearly 20% are infected with 
HIV in patients with HIV-associated dementia (Churchill et al., 2009). Chronically activated 
astrocytes contributes to impaired catabolism of glutamate which results in excitotoxic 
neuronal death and astrocyte apoptosis (Churchill et al., 2009) (González-Scarano & Martín-
García, 2005)(Gorry et al., 2003). The concentration of apoptotic astrocytes may be 
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associated with the speed of HIV dementia progression (McArthur et al., 2005). The 
activation and apoptosis of astrocytes is also a significant cause of blood brain barrier 
compromise as astrocytes are essential for the maintenance of blood brain barrier integrity 
(Churchill et al., 2009)(Gray et al., 2014)(Z. Wang et al., 2004).  
 
Activated astrocytes are the major source for S100β in the inflamed CNS and is a useful 
marker of gliosis and brain damage (Brew & Letendre, 2008)(Donato et al., 2009) (Yardan 
et al., 2011)(Du Pasquier et al., 2013). S100β levels are elevated in several 
neurodegenerative disorders and may play a role in the pathophysiology of 
neurodegeneration and brain inflammatory diseases  (Donato, 1999)(Donato, 2001)(Donato 
et al., 2009). High levels of S100β have been associated with neuronal apoptosis and the 
failure of astrocytes to maintain the integrity of the blood brain barrier (Du Pasquier et al., 
2013). 
 
The evidence for S100β as a biomarker of cognitive impairment in HIV is limited. CSF S100β 
levels may be a marker of severe HAD (Pemberton and Brew (2001)(Yuan et al., 2017). Yet, 
in the clinical setting, the milder cognitive disorders create a diagnostic challenge, and it is in 
those disorders where S100β as a biomarker of cognitive impairment would be most useful 
and necessary. Woods and Iudicello (2011) noted that CSF S100β reflected executive 
dysfunction in HIV, but they did not investigate impairment in other cognitive domains.  
Abassi (2017) demonstrated that elevated levels of CSF S100β were associated with 
decreased odds of developing MND or HAD in ART naïve individuals. Other studies of S100β 
in HIV explored its association with differing ART regimens, but not neurocognitive 
impairment (Du Pasquier et al., 2013) (Estébanez et al., 2014). 
  
There are no longitudinal data on S100β pre- and post-ART (Brew & Letendre, 2008). Such 
longitudinal data may support its use as a marker of astrocyte recovery, as well as change in 
neurocognition. In addition, there are no published South African studies which investigated 
S100β and its relationship to cognition in HAND. This may be key, as the HIV epidemic in SA 
is predominantly Clade C, which exert different neurovirulent effects (Mishra et al., 2008).  
 
AIMS AND OBJECTIVES 
 
1. The primary aim of this study was to determine the association between the levels of 
CSF S100β and neurocognitive function, as measured by the global deficit score 
(GDS) of patients with HIV before the initiation of ART, and after six months on ART.  
2. The secondary aim was to determine if the introduction of ART had an effect on CSF 
S100β levels over time. 
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METHOD 
 
This study forms part of a collaborative research programme into HAND by the Division of 
Neuropsychiatry at the University of Cape Town and the Department of Psychology and 
Behavioural Neuroscience at the University of Missouri-St. Louis (Paul et al., 2014). A large 
database of patient information had been collected and frozen CSF samples were stored at  
-80°C for further investigations. This research project made use of available stored CSF 
samples and clinical data.  
 
Participants of the original HAND study signed informed consent for their information and 
blood and CSF samples to be used for subsequent research. The larger HAND research 
project as well as the current project was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town. 
 
Participants for the study were recruited from 2011 until 2013 from primary health care HIV 
clinics in the Western Cape. Patients who were in the pre-treatment counselling phase for 
ART initiation were identified from the clinical folders. The identified patients were 
approached and screened for probable inclusion in the study. If patients met the inclusion 
criteria and agreed to sign informed consent, visits were scheduled at Groote Schuur 
Hospital. ART was initiated within three months of participation in this study. 
 
Included participants were between 18 and 45 years of age; spoke isiXhosa as primary 
language; were confirmed HIV seropositive documented by ELISA and confirmed by 
Western Blot; were stage B or C according to the Centers for Disease Control and Prevention 
(CDC) criteria; and had at least five years of formal schooling. Participants were excluded 
from the study if they had a comorbid psychiatric or neurologic disorder that could 
significantly affect cognition.  
 
At the time of enrolment in the study, a comprehensive medical and demographic history 
was done, and participants completed the Centers for Epidemiologic Studies Depression 
Scale - Revised (CES-D). Patients with major depression (a cut-off >18) were excluded from 
the study. Blood samples were collected from all participants and stored at  -80˚C. A viral 
load and CD4 count were done on these samples. The neuropsychological testing was done 
by an experienced research technician who is fluent in isiXhosa. Tests were modified to 
ensure cultural relevancy. The battery included measures of learning: verbal learning was 
tested using the Hopkins Learning Test – Revised (HVLT – R) (Brandt & Benedict, 2001) and 
visual learning was assessed with the Brief Visual Memory Test – Revised (Benedict, 
Schretlen, Groninger, Dobraski, & Shpritz, 1996). The gemstones in the list-learning task of 
the HVLT-R were replaced with vegetables to ensure cultural relevancy. We assessed 
executive functioning/ visuospatial abilities using Colour Trails 2 (D’Elia, Satz, Uchiyama, & 
White, 1996), verbal fluency (fruits and animals) and the Block Design from the WAIS-IV 
(Wechsler, 1997).  Finally, psychomotor  speed was tested using Colour Trails 1 (D’Elia et 
al., 1996), the Grooved Pegboard Test (Klove, 1963), Trailmaking Test A (Reitan, 1955), 
Digit Symbol (Wechsler, 2008) and Symbol search (Wechsler, 2008). The Global Deficit 
Score (GDS) was calculated by converting the individual test scores (T-scores) from the 
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neuropsychological battery to a deficit score ranging from zero (no impairment) to five 
(severe impairment) (Blackstone et al., 2012). Subjects with a GDS of < 0.5 was classified 
as neuropsychologically impaired. A GDS cut-off of 0.5 has been demonstrated to provide 
the best balance between sensitivity and specificity in diagnosing neuropsychological 
impairment when compared to clinical ratings (Carey, Woods, Gonzalez, et al., 2004). 
 
On completion of the first study visit, participants were called back and invited to return for 
a CSF sub-study. They signed separate consent to lumbar puncture (LP). Once done, CSF 
aliquots were stored at -80˚C. Participants were invited to return for a follow-up visit six 
months after ART was initiated. At this visit, the neuropsychological battery was repeated, 
serum was taken for viral load and CD4, and another LP was done. The ART regimen that 
patients were taking at that time, was documented. 
 
Only participants in whom both a CSF sample and the GDS score from the initial assessment 
were available were included in this analysis. The CSF samples and recorded data of 46 HIV-
positive participants were used in this study. In 20 of these, a CSF sample from the follow-
up assessment was also available. 
 
EDTA blood samples were collected at the time of enrolment in the study and plasma and 
cell aliquots were stored at −80°C. RNA was isolated from patient samples using the Abbott 
Real-time HIV-1 amplification reagent kit, according to the manufacturer’s instructions. Viral 
load was determined using the Abbott m2000sp and the Abbott m2000rt analysers (Abbott 
laboratories, Abbott Park, Illinois, USA). For CD4 counts, analyses of cells from fresh blood 
samples were completed on the FACSCalibur flow cytometer in conjunction with the 
MultiSET V1.1.2 software (BD Biosciences, San Jose, CA, USA).  
 
Baseline and follow-up CSF S100β protein concentrations were quantified with a 
commercially available ELISA kit (Abnova, KA0037). The analyses were performed according 
to the manufacturers’ guidelines. The intra- and inter-assay coefficients of variation were 
7% and 10%, respectively. 
 
Statistical analyses 
 
All analyses were conducted with SPSS version 22.0. Results were considered statistically 
significant when p-values were <0.05. Baseline and follow-up CSF S100β levels were 
normally distributed with acceptable skewness and kurtosis. 
 
Exploratory analyses were first performed with Spearman’s correlations to determine the 
associations between  
1) baseline CSF S100β levels and cognitive domains at baseline,  
2) correlation between baseline CSF S100β with baseline GDS scores and 
3) association between follow-up CSF S100β with follow-up GDS scores.  
A Bonferroni correction was accounted for the number of cognitive domains tested (α/n = 
0.05/7 = 0.007) in the associations between baseline CSF S100β levels and cognitive 
domains at baseline. Separate regression models would subsequently be used for further 
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analyses with covariates (age, sex, education, nadir CD4 count and viral load) in case 
significant associations were found. An independent sample t-test was performed to 
evaluate differences in baseline CSF S100β levels between HIV patients with cognitive 
impairment vs. without cognitive impairment according to baseline GSD measures. To 
determine whether baseline S100β was associated with changes in GDS at follow-up, linear 
regression analyses were performed with follow-up GDS scores as dependent variable and 
baseline S100β as predictor and baseline GDS as covariate. This was also performed 
separately for nadir CD4 levels and viral load. 
 
RESULTS 
 
Baseline measures were obtained in n=46 patients. Follow-up measures were obtained 
approximately six months after initiation of ART and included neuropsychological 
assessments and S100β levels in n=20 patients. 
 
Table 1 provides a description of the characteristics of the total study sample.  
 
Table 1. Participant characteristics including demographic data, GDS and CSF analysis 
 
 Baseline (n=46) Follow-up (n=20) 
Sex Female n, (%) 44 (95.7) 19 (95.0) 
Age, median (IQR)  30.00 (27.00-34.00)  
Education, years, median 
(IQQ) 
11.00 (10.00-11.00)  
GDS, median (IQR) 0.27 (0.09-0.53) 0. 27 (0.00 – 0.17) 
CD4, median (IQR) 188.00 (134.50-389.50) - 
Plasma viral load (log10) 
copies/ml, median (IQR) 
4.02 (3.40-4.71) - 
CSF viral load (log10) 
copies/ml, median (IQR)   
1.92 (1.60-3.14) - 
CSF protein (g/l), median 
(IQR) 
0.27 (0.22-0.37) - 
CSF S100β (pg/ml), median 
(IQR)   
146.95 (95.93-199.62) 117.05 (87.26-182.18) 
IQR: interquartile range; GDS: Global Deficit Score; CSF: cerebrospinal fluid 
 
The GDS ranged from 0 to 1.6842. In 30.43% (n=14) study participants the GDS was ≥ 0.5 
at baseline. CSF S100β levels ranged from 45.7 pg/ml to 233.84 pg/ml at baseline and from 
54.14 pg/ml to 194.77 pg/ml at follow-up. 
Associations between S100β levels and cognitive 
measures, and study characteristics 
 
No significant associations were found between baseline CSF S100β levels and GDS at 
baseline (r= -0.070; p= 0.66) or at follow-up (r= 0.16, p= 0.52). Baseline CSF S100β levels 
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were also not significantly associated with plasma viral load (r=0.247, p= 0.10) or CD4 
counts (r=0.020, p= 0.90).  
 
Table 2. Correlations between CSF S100β levels at baseline and neurocognitive measures, 
and study characteristics. 
Cognitive domain Tests  Mean (z-scores) R P 
Verbal  Animal fluency -0.40 ± 0.92 0.22 0.17 
Processing speed WAIS-III Digit symbol -0.23 ± 0.75 -0.06 0.71 
WAIS-III Symbol search 
Colour trails I 
Stroop Colour 
Learning HVLT Learning -0.11 ± 0.82 0.11 0.48 
BVMT Learning 
Memory Recall HVLT Delayed recall -0.80 ± 0.54 -0.09 0.58 
BVMT Delayed recall 
Motor Functioning Groove peg board Dominant 0.03 ± 0.59 0.10 0.52 
Groove peg board Non-
dominant 
Executive function Colour trails II -0.20 ± 0.81 0.16 0.32 
GDS  0.35 ± 0.34 -0.07 0.66 
HVLT: Hopkins Verbal Learning Test; BVMT: Brief Visual Memory Test; GDS: Global Deficit Score 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Baseline CSF S100β concentrations in HIV patients without cognitive impairment 
(n=32) vs. HIV patients with cognitive impairment (n=14). An independent sample t-test 
showed that there were no significant differences in CSF S100β levels between patients 
without cognitive impairment vs. cognitive impairment (t=0.102, p=0.919).  Not impaired: 
GDS < 0.5, impaired: GSD ≥ 0.5 
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Figure 2. Correlation between baseline CSF S100β with baseline GDS scores, r=-0.07, 
p=0.66. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Illustration of follow-up CSF S100β concentrations in HIV patients without 
cognitive impairment (n=16) vs. HIV patients with cognitive impairment (n=4). Statistical 
analyses was not performed due to unequal group sizes. Not impaired: GDS < 0.5, 
impaired: GSD ≥ 0.5. 
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Figure 4: Correlation between follow-up CSF S100β with follow-up GDS scores, r=0.16, 
p=0.52. Baseline GDS score was significantly correlated with the follow-up GDS score 
(r=0.81, p<0.001). The follow-up GDS scores declined (mean 0.18 ± 0.26) over this time 
period. In addition, baseline and follow-up CSF S100β levels were significantly correlated 
(r=0.73, p<0.001).  
 
Baseline S100β as predictor of changes in Global Deficit 
Score (GDS) 
 
Because the GDS scores declined over time, we further investigated if baseline CSF S100β 
levels predicted the change in GDS scores (T2-T1). Baseline CSF S100β did not significantly 
predict change in GDS, B(SE) = 0.001, (0.001), β= 0.0.025, p= 0.85. In addition, viral load 
B(SE) = -0.001 (.001), β =-0.21, p=0.133 and nadir CD4 B(SE) = 0.001 (0.001), β =0.24, 
p=0.111 also did not predict the change in GSD scores over time. 
 
DISCUSSION 
 
In this first longitudinal study of S100β in a pre- and post-ART cohort, we did not observe 
an association between the marker and cognitive outcomes. We did note that cognition and 
S100β were significantly correlated at the pre- and post-assessments, confirming reliability 
of our measurements. Nearly one third of participants (30.43%) met GDS criteria for 
cognitive impairment using a cut-off of 0.5 (Blackstone et al., 2012). We noted that S100β 
levels were low at baseline and at follow-up, however these levels were independent of 
cognition. Our sample was predominantly woman (93.8%), entering care with low CD4 
counts. Our findings suggest that S100β may not be useful on its own in monitoring 
cognition in patients with HIV before ART of after 6 months of ART. 
 
Similar to previous studies (Estébanez et al., 2014)(Woods et al., 2010) we found no 
correlation between the CSF S100β level and cognitive impairment as measured by GDS at 
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baseline or at follow-up. This study does not support the findings of Pemberton et al. (2001) 
or Yuan et al. (2017) that demonstrated that CSF S100β was associated with cognitive 
impairment in HIV. However, the patients in those studies had more severe cognitive 
impairment (Pemberton & Brew, 2001), were older (Yuan et al., 2017) and had a lower CD4 
(Yuan et al., 2017) than the patients in our study. This study also does not support the 
findings of Abassi et al.(2017) who demonstrated that elevated CSF S100β were associated 
with decreased odds of MND or HAD in patients with HIV in Uganda. However, this study did 
not investigate the response of S100β on ART and looked at patients with Clade D HIV 
which may have different cognitive outcomes (Paul et al., 2014). 
 
HIV disrupts frontal-subcortical circuits which results in impairment in attention, memory, 
executive function and psychomotor speed (Carey, Woods, Rippeth, et al., 2004)(Carey, 
Woods, Gonzalez, et al., 2004). The subcortical deficits are more prominent in untreated 
disease. The use of a global measure of global cognitive impairment such as the GDS may 
have been unable to detect isolated deficits in specific cognitive domains (Carey, Woods, 
Gonzalez, et al., 2004). However, we found no association between S100β levels and the 
individual domains of executive function, learning and psychomotor speed. This stands in 
contrast to the study by Woods et al. (2011) in which CSF S100β was found to be associated 
with impairments in executive dysfunction as measured by action (verb) fluency, a test 
which was not administered in this study.  
 
Our results show that baseline and follow-up CSF S100β were significantly correlated, which 
confirms the reliability of the CSF S100β measurements at baseline and at follow-up. It also 
demonstrates that CSF S100β levels were not affected by the use of ART, a finding which 
corresponds with other studies (Estébanez et al., 2014)(Pemberton & Brew, 2001).  
 
The mean CSF s100B level at baseline in the current study was 115,61pg/ml. This is much 
lower than in the Estebanez (2014) study where the mean S100B level of patients receiving 
triple therapy was 246,8pg/ml and in patients receiving monotherapy 252,4pg/ml. It is also 
much lower than in the MOST trial where S100β levels were 677pg/ml in the group receiving 
monotherapy and 313pg/ml in the group receiving triple therapy (Du Pasquier et al., 2013). 
However, patients in those studies were older, had been on ART for many years and some 
had a history of neurological diseases. Our cohort was specifically newly treated and 
included mainly women with lower CD4 cell counts. 
 
There was no association between CSF S100β levels and plasma viral load which confirms 
that S100β is not a good biomarker of virological control in HIV (Pemberton & Brew, 
2001)(Estébanez et al., 2014). There was also no association between S100β levels and 
plasma CD4 or CSF protein levels. The fact that there was no association between S100β 
and CD4 is an interesting finding as one would expect a lower nadir CD4 to indicate 
neuronal or glial injury and therefore elevated S100β levels in the CSF. The finding that 
there was no association between S100β levels and age is not surprising as the sample was 
young (mean age 30.68 years) and excluded individuals older than forty-five.  
 
35 
 
CSF S100β was not a predictor of a change in cognition (as measured by the GDS). The 
assumption was that patients with high levels of S100β would have astrocyte damage with 
resultant cognitive impairment which would not respond to ART. The hypothesis in this 
study was therefore that patients with high levels of S100β would have more cognitive 
impairment after at least six months of ART. However, this hypothesis was refuted and 
contradicted the findings of Pemberton and Brew (2001) who demonstrated that S100β 
levels were higher in individuals who progressed rapidly to death. However, in the 
Pemberton study, patients were not initiated on ART and most of the subjects in the study 
had severe HAND. In a 2011 review, Yardan et al (2011) argued that S100β has potential in 
predicting the efficiency of treatment and prognosis in patients with neurological disorders. 
We did not find this to be the case in a South African HAND population. 
 
The mean GDS prior to initiation of ART was low. This is clinically relevant as milder forms of  
cognitive impairment are most prevalent (Joska et al., 2011),  the most difficult to diagnose, 
and the disorder where a biomarker would be the most useful to assist with the diagnosis. 
We noted, as expected, that significant improvements occurred over time in individuals on 
ART. As we did not specifically control for practice effects, we cannot conclusively say 
whether these effects are due to ART only. 
 
The majority of the study population was female which could be explained by the fact that 
the incidence and prevalence of HIV is much higher among females than males in South 
Africa (Statistics South Africa, 2015)(Vandormael, Akullian, Dobra, De Oliveira, & Tanser, 
2018). However, the ratio of female to male participants in this study is much higher than 
the national ratio (Statistics South Africa, 2015). The mean age of participants in this study 
was much lower than in similar studies looking at S100β in the CSF (Estébanez et al., 
2014)(Woods et al., 2010). However, the younger age of participants in this study reflects 
the South African demographic, as  HIV is more prevalent among younger individuals in 
South Africa (Statistics South Africa, 2015) and the mean age of patients who were initiated 
on ART in primary health care clinics in South Africa, was 29,5 years (Joska et al., 2011). 
Additionally, only patients between the ages of eighteen and forty-five were included in 
order to avoid age-related central nervous system abnormalities (Paul et al., 2014).  
 
The low nadir CD4 of study participants could have resulted in chronic neuronal injury which 
could explain the mild cognitive impairment that was present in many of the study 
participants. The current guidelines of the National Department of Health in South Africa 
state that HIV positive patients should be initiated on ART irrespective of their CD4 count 
(Meintjes et al., 2017). However, at the time that the study was done, South African 
guidelines recommended that ART should be initiated in HIV positive patients with a CD4 
count of less than 350 cells/μl (Cross, Combrinck, & Joska, 2013). This could account for the 
low CD4 of participants in this study. Another explanation could be that patients often get 
tested late in the disease and enter care when their CD4 counts are low. 
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LIMITATIONS OF STUDY 
 
A significant limitation of the study is the small sample size. This study involved the 
performance of additional tests on CSF samples that were collected in another study. The 
evidence collected in this study was therefore limited by the information collected and the 
availability of CSF samples from the original study. The CSF samples of 46 participants were 
available at baseline, and the CSF samples of 20 participants were available both at baseline 
and after six months of ART. Yet, to our knowledge it is still the largest longitudinal study of 
its kind. Other studies tested the CSF S100β levels of a larger number of participants at 
baseline, but did not repeat these investigations at a later stage or subsequent to the 
initiation of ART (Woods et al., 2010)(Pemberton & Brew, 2001)(Estébanez et al., 
2014)(Abassi et al., 2017)(Yuan et al., 2017). 
 
Certain factors which may affect the association between neurological functioning and 
S100β, such as other chronic somatic diseases and psychological trauma, were not 
controlled for in this study. 
 
Another limitation was the fact that the mean GDS of the group was low, and that the 
majority of patients had mild cognitive impairment. This could be a reason why no 
statistically significant association was detected between the degree of cognitive impairment 
and the level of S100β in the CSF. However, the low mean GDS of the sample is clinically 
beneficial, as most patients have milder degrees of HAND (Joska et al., 2011) and mild 
cognitive impairment is much more difficult to diagnose. 
 
The large number of female subjects is another limitation, as our sample was not 
representative of the South African population with HIV.  
 
Due to these limitations, future studies are necessary to determine the effect of CSF S100β 
on ART in patients with HAND. Such studies should be larger, be more representative of the 
South African population and investigate the response of CSF S100β over a period of more 
than six months. 
 
CONCLUSIONS 
 
In conclusion, CSF S100β is not a marker of cognitive impairment in younger mainly female 
Xhosa-speaking patients with HIV infection in a South African primary health setting. In this 
group of patients, there was no association between CSF S100β levels and impairment of 
cognitive domains that are usually affected by HIV. CSF S100β was also not a good 
predictor of the effect of ART on patients’ cognitive functioning. However, the sustained 
levels of CSF S100β over time indicate that neuroinflammatory processes remain regardless 
of ART. 
 
  
37 
 
BIBLIOGRAPHY 
 
Abassi, M., Morawski, B. M., Nakigozi, G., Nakasujja, N., Kong, X., Meya, D. B., & Robertson, 
K. (2017). Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders 
in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 23(3), 369–375.  
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., … Epstein, L. G. 
(2007). Updated research nosology for HIV-associated neuro cognitive disorders. 
Neurology, 69, 1789–1799.  
Benedict, R. H., Schretlen, D., Groninger, L., Dobraski, M., & Shpritz, B. (1996). Revision of 
the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and 
validity. Psychological Assessment, 8(2), 145–153. 
Blackstone, K., Moore, D. J., Franklin, D. R., Clifford, D. B., Collier, A. C., & Marra, C. . 
(2012). Defining Neurocognitive Impairment in HIV: Deficit Scores versus Clinical 
Ratings. Clinical Neuropsychologist, 26(6), 1–11. 
Brandt, J., & Benedict, R. (2001). Hopkins Verbal Learning Test-Revised: Professional 
Manual. Psychological Assessment Resources. 
Brew, B. J., & Letendre, S. L. (2008). Biomarkers of HIV related central nervous system 
disease. International Review of Psychiatry, 20(1), 73–88.  
Carey, C. L., Woods, S. P., Gonzalez, R., Conover, E., Marcotte, T. D., Grant, I., & Heaton, 
R. K. (2004). Predictive validity of global deficit scores in detecting neuropsychological 
impairment in HIV infection. Journal of Clinical and Experimental Neuropsychology, 
26(3), 307–319.  
Carey, C. L., Woods, S. P., Rippeth, J. D., Gonzalez, R., Moore, D. J., Marcotte, T. D., … 
Heaton, R. K. (2004). Initial validation of a screening battery for the detection of HIV-
associated cognitive impairment. Clinical Neuropsychologist, 18(2), 234–248.  
Cherner, M., Masliah, E., Ellis, R. J., Marcotte, T. D., Moore, D. J., & Grant, I. (2002). 
Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. 
Neurology, 59(10), 1563–1567. 
Churchill, M. J., Wesselingh, S. L., Cowley, D., Pardo, C. A., McArthur, J. C., Brew, B. J., & 
Gorry, P. R. (2009). Extensive astrocyte infection is prominent in human 
immunodeficiency virus - associated dementia. Annals of Neurology, 66(2), 253–258.  
Cross, H. M., Combrinck, M. I., & Joska, J. A. (2013). HIV-associated neurocognitive 
disorders: Antiretroviral regimen, central nervous system penetration effectiveness, and 
cognitive outcomes. South African Medical Journal, 103(10), 758–762.  
D’Elia, L., Satz, P., Uchiyama, C., & White, T. (1996). Color Trails Test. In Psychological 
Assessment Resources. Odessa, FL. 
Donato, R. (1999). Functional roles of S100 proteins, calcium-binding proteins of the EF-
hand type. Biochimica et Biophysica Acta - Molecular Cell Research, 1450(3), 191–231.  
 
 
38 
 
Donato, R. (2001). S100: A multigenic family of calcium-modulated proteins of the EF-hand 
type with intracellular and extracellular functional roles. International Journal of 
Biochemistry and Cell Biology, 33(7), 637–668.  
Donato, R., Sorci, G., Riuzzi, F., Arcuri, C., Bianchi, R., Brozzi, F., … Giambanco, I. (2009). 
S100B’s double life: Intracellular regulator and extracellular signal. Biochimica et 
Biophysica Acta - Molecular Cell Research, 1793(6), 1008–1022.  
Du Pasquier, R. A., Jilek, S., Kalubi, M., Yerly, S., Fux, C. A., Gutmann, C., … Vernazza, P. L. 
(2013). Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of 
HIV-infected patients on LPV/r-monotherapy. Aids, 27(2), 203–210.  
Estébanez, M., Stella-Ascariz, N., Mingorance, J., Pérez-Valero, I., González-Baeza, A., 
Bayón, C., … Arribas, J. R. (2014). A comparative study of neurocognitively impaired 
patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. 
Journal of Acquired Immune Deficiency Syndromes, 67(4), 419–423.  
Eugenin, E. A., & Berman, J. W. (2007). NIH Public Access. Journal of Neuroscience, 27(47), 
12844–12850.  
Floyd, E., & Mcshane, T. M. (2004). Development and Use of Biomarkers in Oncology Drug 
Development. Toxicologic Pathology, 32(1_suppl), 106–115.  
González-Scarano, F., & Martín-García, J. (2005). The neuropathogenesis of AIDS. Nature 
Reviews Immunology, 5(1), 69–81.  
Gorry, P. R., Ong, C., Thorpe, J., Bannwarth, S., & Thompson, K. A. (2003). Astrocyte 
Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the 
Pathogenesis of HIV-1-Associated Dementia. Current HIV Research, 1(4), 463–473. 
Grant, I., Franklin, D. R., Deutsch, R., Woods, S. P., Vaida, F., Ellis, R. J., … CHARTER 
Group. (2014). Asymptomatic HIV-associated neurocognitive impairment increases risk 
for symptomatic decline. Neurology, 82(23), 2055–2062.  
Gray, L. R., Turville, S. G., HItchen, T. L., Cheng, W. J., Ellett, A. M., Salimi, H., … Churchill, 
M. J. (2014). HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS 
ONE, 9(2), 1–8.  
Heaton, R. K., Clifford, D. B., Franklin, D. R., Woods, S. P., Ake, C., Vaida, F., … Grant, I. 
(2010). HIV-associated neurocognitive disorders persist in the era of potent 
antiretroviral therapy: Charter Study. Neurology, 75(23), 2087–2096.  
Janse van Rensburg, B. (2012). The South African Society of Psychiatrists (SASOP) and 
SASOP State Employed Special Interest Group (SESIG) position statements on 
psychiatric care in the public sector. South African Journal of Psychiatry, 18(3), 133–
148.  
Janssen, R. S., Nwanyanwu, O. C., Selik, R. M., & Stehr-Green, J. K. (1992). Epidemiology of 
human immunodeficiency virus encephalopathy in the United States. Neurology, 42(8). 
Joska, J. A., Westgarth-Taylor, J., Myer, L., Hoare, J., Thomas, K. G. F., Combrinck, M., … 
Flisher, A. J. (2011). Characterization of HIV-Associated Neurocognitive Disorders 
among individuals starting antiretroviral therapy in South Africa. AIDS and Behavior, 
15(6), 1197–1203.  
 
39 
 
Klove, H. (1963). Clinical Neuropsychology. Medical Clinics of North America, 47, 1647. 
McArthur, J. C. (2004). HIV dementia: An evolving disease. Journal of Neuroimmunology, 
157(1–2 SPEC. ISS.), 3–10.  
McArthur, J. C., Brew, B. J., & Nath, A. (2005). Neurological complications of HIV infection. 
Lancet Neurology, 4(9), 543–555.  
Meintjes, G., Moorhouse, M. A., Carmona, S., Davies, N., Dlamini, S., & Van Vuuren, C. 
(2017). Adult antiretroviral therapy guidelines 2017. Southern African Journal of HIV 
Medicine, 18(1), 1–24. 
Mishra, M., Vetrivel, S., Siddappa, N. B., Ranga, U., & Seth, P. (2008). Clade-specific 
differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human 
neurons: Significance of dicysteine C30C31 motif. Annals of Neurology, 63(3), 366–376.  
Morris, K. A., Davis, N. W., & Brew, B. (2010). A guide to interpretation of 
neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV 
central nervous system disease. Neurobehavioral HIV Medicine, 59.  
Paul, R. H., Joska, J. A., Woods, C., Seedat, S., Engelbrecht, S., Hoare, J., … Stein, D. J. 
(2014). Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological 
function in patients with clade C disease. Journal of NeuroVirology, 20(6), 627–635.  
Pemberton, L. A., & Brew, B. J. (2001). Cerebrospinal fluid S-100beta and its relationship 
with AIDS dementia complex. Journal of Clinical Virology : The Official Publication of the 
Pan American Society for Clinical Virology, 22(3), 249–253. 
Price, R. W., Epstein, L. G., Becker, J. T., Cinque, P., Gisslen, M., Pulliam, L., & McArthur, J. 
C. (2007). Biomarkers of HIV-1 CNS infection and injury. Neurology, 69(18), 1781–
1788.  
Reitan, R. M. (1955). The relation of the Trail Making Test to organic brain damage. Journal 
of Consulting Psychology, 19(5), 393–394. 
Russell, R. A., Chojnacki, J., Jones, D. M., Eggeling, C., Padilla-parra, S., Sattentau, Q. J., … 
Eggeling, C. (2017). Astrocytes resist HIV-1 fusion but engulf infected macrophage 
material article astrocytes resist HIV-1 fusion but engulf infected macrophage material. 
CellReports, 18(6), 1473–1483.  
Statistics South Africa. (2015). Mid-year population estimates 2016. Statistics South Africa. 
Steiner, J., Bernstein, H., Bielau, H., Berndt, A., Brisch, R., Mawrin, C., … Bogerts, B. (2007). 
Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC 
Neuroscience, 8(2), 1–10.  
Takahashi, T., Wesselingh, S. L., & Griffin, D. (1996). Localization of HIV-1 in human brain 
using polymerase chain reaction/ in situ hybridization and immunocytochemistry. 
Annals of Neurology, 39, 705–711. 
Vandormael, A., Akullian, A. N., Dobra, A., De Oliveira, T., & Tanser, F. (2018). Sharp 
decline in male HIV incidence in a rural South African population (2004 - 2015). In 
Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 
Massachusetts. 
 
40 
 
Wang, T., Gong, N., Liu, J., Kadiu, I., Kraft-terry, S. D., Schlautman, J. D., … Howard, E. 
(2009). NIH Public Access, 3(3), 173–186.  
Wang, Z., Trillo-Pazos, G., Kim, S.-Y., Canki, M., Morgello, S., Sharer, L. R., … Volsky, D. J. 
(2004). Effects of human immunodeficiency virus type 1 on astrocyte gene expression 
and function: Potential role in neuropathogenesis. Journal of Neurovirology, 10(1), 25–
32.  
Wechsler, D. (1997). Wechsler Adult Intelligence Scale - Third Edition. 
Wechsler, D. (2008). Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV). San 
Antonio, TX: NCS Pearson. 
Woods, S. P., Iudicello, J. E., Dawson, M. S., Weber, E., & Grant, I. (2010). HIV-associated 
deficits in action (verb) generation may reflect astrocytosis. Journal of Clinical and 
Experimental Neuropsychology, 32(5), 522–527.  
Yardan, T., Erenler, A. K., Baydin, A., Aydin, K., & Cokluk, C. (2011). Usefulness of S100B 
protein in neurological disorders. Journal of the Pakistan Medical Association, 61(3), 
276–281. 
Yuan, L., Wei, F., Zhang, X., Guo, X., Lu, X., Su, B., … Chen, D. (2017). Intercellular 
Adhesion Molecular-5 as Marker in HIV Associated Neurocognitive Disorder. Ageing and 
Disease, 8(3), 250–256. 
 
